

# Michael Thomas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2160391/publications.pdf>

Version: 2024-02-01

126  
papers

10,325  
citations

101543

36  
h-index

34986

98  
g-index

137  
all docs

137  
docs citations

137  
times ranked

11339  
citing authors

#	ARTICLE	IF	CITATIONS
1	Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 251-265.	4.2	22
2	Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery. <i>Lung Cancer</i> , 2022, 164, 46-51.	2.0	3
3	TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy of EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. <i>Translational Lung Cancer Research</i> , 2022, 11, 4-13.	2.8	13
4	Histological and Molecular Plasticity of ALK-positive Non-Small-Cell Lung Cancer under Targeted Therapy - a Case Report. <i>Journal of Physical Education and Sports Management</i> , 2022, , mcs.a006156.	1.2	5
5	MARIPOSA: phase 3 study of first-line amivantamab plus azaotentinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 639-647.	2.4	44
6	A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy. <i>Npj Precision Oncology</i> , 2022, 6, 19.	5.4	20
7	Impact of molecular alterations on quality of life and prognostic understanding over time in patients with incurable lung cancer: a multicenter, longitudinal, prospective cohort study. <i>Supportive Care in Cancer</i> , 2022, 30, 3131-3140.	2.2	2
8	Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. <i>Cancers</i> , 2022, 14, 2479.	3.7	3
9	The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. <i>European Journal of Cancer</i> , 2022, 170, 106-118.	2.8	15
10	Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib. <i>Cancers</i> , 2022, 14, 2720.	3.7	5
11	Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100369.	1.1	3
12	Abstract 3374: Large-scale single-cell whole transcriptomic analyses reveal distinct malignant phenotypes of CTCs from NSCLC patients. <i>Cancer Research</i> , 2022, 82, 3374-3374.	0.9	1
13	Heidelberger Meilenstein Kommunikation (HeiMeKOM), ein interprofessionelles Kommunikationskonzept für Patient:innen mit Lungenkrebs und eingeschränkter Prognose: Ergebnisse einer mixed-methods Studie. <i>Pneumologie</i> , 2022, , .	0.1	0
14	Die seltene thorakale Manifestation eines extramedullären Myeloms. <i>Pneumologie</i> , 2022, , .	0.1	0
15	Wenn Lungenkrebs die Lebensplanung erschwert: Studie zur Erfassung der individuellen Werte von Lungenkrebspatient:innen mit der Human Values Scale. <i>Pneumologie</i> , 2022, , .	0.1	0
16	Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). <i>Lung Cancer</i> , 2021, 152, 174-184.	2.0	53
17	A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol. <i>Clinical Lung Cancer</i> , 2021, 22, 142-146.	2.6	10
18	Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat. <i>Clinical and Translational Science</i> , 2021, 14, 487-491.	3.1	9

#	ARTICLE	IF	CITATIONS
19	Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199650.	3.2	24
20	A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. <i>OncImmunity</i> , 2021, 10, 1860586.	4.6	40
21	Lung cancer patients' comorbidities and attendance of German ambulatory physicians in a 5-year cross-sectional study. <i>Npj Primary Care Respiratory Medicine</i> , 2021, 31, 2.	2.6	3
22	Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. <i>Lung Cancer</i> , 2021, 153, 150-157.	2.0	45
23	Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course. <i>Oncologist</i> , 2021, 26, e1058-e1065.	3.7	42
24	De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 640048.	2.8	4
25	Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field. <i>Lung Cancer</i> , 2021, 154, 131-141.	2.0	8
26	Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition. <i>Cancers</i> , 2021, 13, 1812.	3.7	1
27	Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 670483.	2.8	10
28	Earlier extracranial progression and shorter survival in ALK- rearranged lung cancer with positive liquid rebiopsies. <i>Translational Lung Cancer Research</i> , 2021, 10, 2118-2131.	2.8	16
29	Effects of an Interprofessional Communication Approach on Support Needs, Quality of Life, and Mood of Patients with Advanced Lung Cancer: A Randomized Trial. <i>Oncologist</i> , 2021, 26, e1445-e1459.	3.7	8
30	Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial. <i>BMC Cancer</i> , 2021, 21, 743.	2.6	3
31	Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 703893.	2.8	33
32	Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer. <i>ESMO Open</i> , 2021, 6, 100161.	4.5	9
33	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 959-969.	10.7	222
34	Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. <i>ESMO Open</i> , 2021, 6, 100254.	4.5	35
35	The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma. <i>ESMO Open</i> , 2021, 6, 100253.	4.5	17
36	A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199650.	3.2	1

#	ARTICLE	IF	CITATIONS
37	Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican. <i>Cancers</i> , 2021, 13, 208.	3.7	10
38	Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. <i>Npj Precision Oncology</i> , 2021, 5, 100.	5.4	21
39	A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. <i>Investigational New Drugs</i> , 2020, 38, 1145-1155.	2.6	14
40	Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives. <i>Translational Lung Cancer Research</i> , 2020, 9, 1000-1014.	2.8	9
41	Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing. <i>Lung Cancer</i> , 2020, 148, 105-112.	2.0	26
42	Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Administration Rates. <i>Frontiers in Oncology</i> , 2020, 10, 586449.	2.8	15
43	Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. <i>EBioMedicine</i> , 2020, 62, 103103.	6.1	32
44	Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme. <i>Clinical Lung Cancer</i> , 2020, 22, 332-340.e3.	2.6	11
45	Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression: Discovery and Validation Studies. <i>Cancers</i> , 2020, 12, 3834.	3.7	1
46	Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa038.	0.7	14
47	Implementation of the milestones communication approach for patients with limited prognosis: evaluation of intervention fidelity. <i>BMC Palliative Care</i> , 2020, 19, 21.	1.8	10
48	Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. <i>Lung Cancer</i> , 2020, 142, 114-119.	2.0	28
49	Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors. <i>Cancers</i> , 2020, 12, 1046.	3.7	47
50	Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. <i>ESMO Open</i> , 2020, 5, e000567.	4.5	7
51	Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages. <i>Cancers</i> , 2020, 12, 954.	3.7	3
52	Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial. <i>Trials</i> , 2020, 21, 352.	1.6	7
53	Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients. <i>Journal of Thoracic Disease</i> , 2020, 12, 782-793.	1.4	12
54	Genome-Wide DNA Methylation Profiling in Early Stage I Lung Adenocarcinoma Reveals Predictive Aberrant Methylation in the Promoter Region of the Long Noncoding RNA PLUT: An Exploratory Study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1338-1350.	1.1	8

#	ARTICLE	IF	CITATIONS
55	Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9515-9515.	1.6	57
56	Disease monitoring and TKI resistance mutations of EGFR mutation-positive NSCLC patients via circulating tumor DNA.. Journal of Clinical Oncology, 2020, 38, e21627-e21627.	1.6	1
57	CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, TPS9075-TPS9075.	1.6	6
58	Bronchoskopische Rebiopsie bei Patienten mit Lungenkarzinom. , 2020, 74, .		0
59	Clinical and molecular profile of de novo vs. secondary EGFR mutated metastatic non-small-cell lung cancer. Pneumologie, 2020, 74, .	0.1	0
60	Optimizing panel-based tumor mutational burden (TMB) measurement. Annals of Oncology, 2019, 30, 1496-1506.	1.2	123
61	Symptoms and Needs of Patients with Advanced Lung Cancer: Early Prevalence Assessment. Oncology Research and Treatment, 2019, 42, 650-659.	1.2	20
62	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. Journal of Thoracic Oncology, 2019, 14, 1935-1947.	1.1	69
63	Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival. Cancers, 2019, 11, 124.	3.7	36
64	Impact of EMT in stage I/II/III/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab. Oncology Letters, 2019, 17, 4891-4900.	1.8	3
65	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	5.1	76
66	Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIA non-small-cell lung cancer (NSCLC): the NEOMUN trial. BMC Cancer, 2019, 19, 413.	2.6	57
67	Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in ALK-rearranged lung cancer. Journal of Physical Education and Sports Management, 2019, 5, a004630.	1.2	13
68	Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. International Journal of Cancer, 2019, 145, 649-661.	5.1	85
69	Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. International Journal of Cancer, 2019, 144, 848-858.	5.1	131
70	Identification of a highly lethal V3 <sup>+</sup> TP53 <sup>+</sup> subset in ALK <sup>+</sup> lung adenocarcinoma. International Journal of Cancer, 2019, 144, 190-199.	5.1	67
71	The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC. Frontiers in Oncology, 2019, 9, 1550.	2.8	26
72	Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9008-9008.	1.6	75

#	ARTICLE	IF	CITATIONS
73	Defining molecular risk in ALK+ NSCLC. <i>Oncotarget</i> , 2019, 10, 3093-3103.	1.8	35
74	TP53 status conversion defines an unfavourable patient subset with inferior overall survival in ALK+ lung adenocarcinoma. , 2019, 73, .		0
75	A framework for risk stratification in EGFR+ lung adenocarcinoma treated with tyrosine kinase inhibitors. , 2019, 73, .		0
76	Konzeptentwicklung und -Anpassung für eine komplexe Intervention: Heidelberger Meilenstein-Kommunikation (HeiMeKOM) am Beispiel Lungenkrebspatienten mit Prognose <math>\leq 12</math> Monate. <i>Pneumologie</i> , 2019, 73, .	0.1	0
77	Frequency and clinical impact of atypical EGFR mutations in lung adenocarcinoma. , 2019, 73, .		0
78	Clinical predictors of immune checkpoint inhibitor efficacy in non-small cell lung cancer. , 2019, 73, .		0
79	Totality of evidence in development of the bevacizumab biosimilar ABP 215: Central and investigator evaluation of efficacy from the MAPLE study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20708-e20708.	1.6	0
80	Early assessment of therapy response in non-small cell lung cancer (NSCLC) via longitudinal ctDNA analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20701-e20701.	1.6	0
81	Assessing the impact of clonal hematopoiesis in disease monitoring using targeted cell-free DNA (cfDNA) sequencing technology.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14530-e14530.	1.6	0
82	Evaluation of TMB estimates for the prediction of response to immune checkpoint blockade.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2632-2632.	1.6	4
83	Exercise behavior and physical fitness in patients with advanced lung cancer. <i>Supportive Care in Cancer</i> , 2018, 26, 2725-2736.	2.2	7
84	<i>EML4-ALK</i> fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK <sup>+</sup> non-small cell lung cancer. <i>International Journal of Cancer</i> , 2018, 142, 2589-2598.	5.1	93
85	Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance. <i>Lung Cancer</i> , 2018, 119, 48-55.	2.0	21
86	A longitudinal communication approach in advanced lung cancer: A qualitative study of patients', relatives' and staff's perspectives. <i>European Journal of Cancer Care</i> , 2018, 27, e12794.	1.5	17
87	Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians. <i>Translational Lung Cancer Research</i> , 2018, 7, 703-715.	2.8	152
88	EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK+ NSCLC. <i>Journal of Thoracic Disease</i> , 2018, 10, S1989-S1991.	1.4	26
89	Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC. <i>Cancers</i> , 2018, 10, 486.	3.7	11
90	Erlotinib. <i>Recent Results in Cancer Research</i> , 2018, 211, 1-17.	1.8	17

#	ARTICLE	IF	CITATIONS
91	Deficient CD247 expression is a typical histopathological characteristic of thymomas with cortical features. <i>Histopathology</i> , 2018, 73, 1040-1043.	2.9	5
92	Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study. <i>Annals of Oncology</i> , 2018, 29, 2076-2084.	1.2	74
93	The Heidelberg Milestones Communication Approach (MCA) for patients with prognosis <math>\leq 12\text{ months}</math>: protocol for a mixed-methods study including a randomized controlled trial. <i>Trials</i> , 2018, 19, 438.	1.6	18
94	ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer. <i>Medical Oncology</i> , 2018, 35, 106.	2.5	5
95	AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients. <i>International Journal of Oncology</i> , 2017, 50, 365-372.	3.3	110
96	Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial. <i>Annals of Oncology</i> , 2017, 28, 1898-1902.	1.2	53
97	A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3- $\beta$ glucan; Imprime PGC) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , 2017, 35, 345-358.	2.6	40
98	Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. <i>Lung Cancer</i> , 2017, 112, 181-187.	2.0	40
99	Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma. <i>Oncotarget</i> , 2016, 7, 71285-71297.	1.8	13
100	POSITIVE study: physical exercise program in non-operable lung cancer patients undergoing palliative treatment. <i>BMC Cancer</i> , 2016, 16, 499.	2.6	23
101	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3740-3748.	1.6	438
102	Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients. <i>Scientific Reports</i> , 2016, 6, 33505.	3.3	44
103	Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. <i>Lung Cancer</i> , 2016, 93, 95-103.	2.0	41
104	Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas. <i>European Journal of Medical Research</i> , 2015, 20, 64.	2.2	34
105	Psychometric evaluation of the German Version of the Supportive Care Needs Survey for Partners and Caregivers (SCNS-P&C-G) of cancer patients. <i>European Journal of Cancer Care</i> , 2015, 24, 884-897.	1.5	21
106	Ion therapy within the trimodal management of superior sulcus tumors: the INKA trial. <i>BMC Cancer</i> , 2015, 15, 192.	2.6	10
107	Erlotinib and bevacizumab <i>versus</i> cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2015, 46, 219-229.	6.7	14
108	Glycodelin: A New Biomarker with Immunomodulatory Functions in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3529-3540.	7.0	45

#	ARTICLE	IF	CITATIONS
109	EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. <i>European Respiratory Journal</i> , 2014, 43, 872-883.	6.7	97
110	Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study. <i>Current Medical Research and Opinion</i> , 2014, 30, 447-461.	1.9	33
111	Exercise in Patients with Non-Small Cell Lung Cancer. <i>Medicine and Science in Sports and Exercise</i> , 2014, 46, 656-663.	0.4	62
112	Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2014, 370, 1189-1197.	27.0	1,367
113	Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. <i>British Journal of Cancer</i> , 2014, 111, 1222-1229.	6.4	114
114	Depression, anxiety and disease-related distress in couples affected by advanced lung cancer. <i>Lung Cancer</i> , 2014, 86, 274-280.	2.0	47
115	Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. <i>Lancet</i> , 2014, 384, 665-673.	13.7	1,068
116	Physical Performance and Psychosocial Status in Lung Cancer Patients: Results from a Pilot Study. <i>Oncology Research and Treatment</i> , 2014, 37, 36-41.	1.2	15
117	Endogenous anti-Î²-glucan antibodies as a potential predictive biomarker for clinical response to imprime PGG immunotherapy in non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3045-3045.	1.6	3
118	Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer. <i>Anticancer Research</i> , 2014, 34, 3707-13.	1.1	6
119	Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 2385-2394.	27.0	3,181
120	Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. <i>Lancet Oncology</i> , 2012, 13, 247-255.	10.7	549
121	Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 460, 407-414.	2.8	64
122	Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer. <i>Pneumologie</i> , 2011, 65, 39-59.	0.1	133
123	Phase I study of lapatinib, a dual-tyrosine kinase inhibitor, and pemetrexed in the second-line treatment of advanced or metastatic non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, e19027-e19027.	1.6	2
124	Mesenchymal Stromal Cells Derived from Human Non-Small Cell Lung Cancer, Normal Lung Tissue, and Bone Marrow: Differences in Frequency, Cytogenetics, Proliferation Behavior, and Chemosensitivity - Implications for Cancer Therapy.. <i>Blood</i> , 2007, 110, 1925-1925.	1.4	0
125	Grading of Tumor Regression in Non-small Cell Lung Cancer. <i>Chest</i> , 2001, 120, 1584-1591.	0.8	152
126	Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997, 123, 469-477.	2.5	150